Shree Dhanvantary Pharmacy College

16 February 2018

Wanted Stores Incharge / Assistant at SDPC

Shree Dhanvantary Pharmacy College (SDPC), established in 2005 by Shree Sahkar Education Trust, Surat. During this brief tenure of eleven years, it has made rapid strides of progress to become one of the premier institutes of Pharmacy in Gujarat. This institute is approved by AICTE, PCI & affiliated to GTU and currently offering B.Pharm, M.Pharm (Pharmaceutical Chemistry, Pharmaceutics, Pharmacology & Quality Assurance), Pharm.D. & Ph. D. courses.

Post : Stores Incharge / Assistant

8 February 2018

Recruitment for Professor at Shree Dhanvantary Pharmacy College | 07 posts

Shree Dhanvantary Pharmacy College (SDPC), established in 2005 by Shree Sahkar Education Trust, Surat. During this brief tenure of eleven years, it has made rapid strides of progress to become one of the premier institutes of Pharmacy in Gujarat. This institute is approved by AICTE, PCI & affiliated to GTU and currently offering B.Pharm, M.Pharm (Pharmaceutical Chemistry, Pharmaceutics, Pharmacology & Quality Assurance), Pharm.D. & Ph. D. courses.

Post : Professor

25 January 2018

Recruitment for Assistant Professor (07 posts) at Shree Dhanvantary Pharmacy College

Shree Dhanvantary Pharmacy College is pioneer educational institute and research centre in south Gujarat region. The institute is located in the sprawling campus of 8.32 acres, in Kim. Shree Dhanvantary Pharmacy College has built its own credentials in a short span of 10 years.

Post : Assistant Professor

1 May 2017

Vacancy for Research Associate, Research Assistant at SDPARC - 3 posts

Shree Dhanvantary Pharmaceutical Analysis and Research Centre (SDPARC) is a contract research organization established in 2006 and is managed by RIBOSOME PHARMA PVT. LTD., Surat. SDPARC offers a wide range of analytical & research services for small, medium and large scale pharmaceutical, ayurvedic, bulk drug, chemical, food and cosmetic industries.

Post : Research Associate (Pharmacology)- 1 Post; and Research Assistant (Pharmacology)- 2 Posts

6 March 2016

4th International Conference on Theranostic Nanoparticles at Shree Dhanvantary Pharmacy College

9 February 2016

Job as QA Executive, AR&D / QC Executive, Chemical and Store Section Executives in SDPARC - 4 posts

Shree Dhanvantary Pharmaceutical Analysis and Research Centre (SDPARC) is a contract research organization established in 2006 and is managed by RIBOSOME PHARMA PVT. LTD., Surat. SDPARC offers a wide range of analytical & research services for small, medium and large scale pharmaceutical, ayurvedic, bulk drug, chemical, food and cosmetic industries. The centre is approved by the Food and Drug Control Administration (FDCA), Gujarat state as a public testing laboratory and is spread over 8,000 sq. ft. area.

27 January 2016

REVIEW: COMBINED CANDESARTAN CILEXETIL AND PIOGLITAZONE HYDROCHLORIDE THERAPY IN METABOLIC SYNDROME

{ DOWNLOAD AS PDF }

18 January 2016

PHARMACOLOGY OF COMBINED MESALZINE AND RIFAXIMIN THERAPY TO INFLAMMATORY BOWEL DISEASE

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Prajapati Krishna V*, Raj Hasumati A, Jain Vinit C, Prajapati Neelam S.
Department of Quality Assurance,
Shree Dhanvantary Pharmacy College, Kim, Surat, Gujarat, India
*krish1112k@gmail.com

ABSTRACT
This review article presents the pharmacology of combined Mesalazine and Rifaximin therapy especially in inflammatory bowel disease. Mesalazine is used as in anti-inflammatory agent, Non-Steroidal. Rifaximin is used in Gastrointestinal Agents, Anti-infective agent. The use of Rifaximin in combination with Mesalazine has been proved to provide beneficial effect in inflammatory bowel disease. The mechanism of Mesalazine and Rifaximin is quite different. Mesalamine and Rifaximin are two different types of drugs offering some symptomatic relief to the IBD patients. Mesalamine treats inflammation, whereas, Rifaximin reduces bio burden.
Patent for combination of both drugs were approved by WIPO. The main objective of this review article is to provide pharmacological information of combined therapy of Mesalazine and Rifaximin to researcher in development of combined dosage form of this.